Study of REM-422 in Patients With AML or Higher Risk MDS
NCT06297941
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndromes
Higher Risk Myelodysplastic Syndromes
Acute Myeloid Leukemia
Acute Myeloid Leukemia Refractory
Interventions
DRUG:
REM-422
Sponsor
Remix Therapeutics